Indication
Details coming soon
Details coming soon
| Clinical Information | Administration Information |
|---|---|
|
Age: Adults |
Dose: Inhaler – 250/10 micrograms Frequency: 2 inhalations (puffs) twice daily |
|
Age: Adults |
Dose: Inhaler – 50/5 micrograms Frequency: 2 inhalations (puffs) twice daily Note: Normally taken in the morning and in the evening. |
| Clinical Information | Administration Information |
|---|---|
|
Age: less than 12 years |
Dose: Not recommended |
|
Age: Adolescents aged 12 years and above |
Dose: Inhaler – 50 /5 mcg Frequency: 2 inhalations (puffs) twice daily Note: normally taken in the morning and in the evening |
| Drug Name | Risk Factors |
|---|---|
|
CYP3A4 inhibitors (e.g. ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nelfinavir, saquinavir, ketoconazole, telithromycin)
|
Increased plasma concentration with long-term treatment
|
|
Non-K sparing diuretics (loop or Thiazide diuretics (Chlorothiazide, Chlorthalidone, Hydrochlorothiazide, Indapamide, Metolazone)), Xanthine Derivatives (Theophylline, Aminophylline, Caffeine), glucoCorticosteroids (Prednisone, Prednisolone, Methylprednisolone, Dexamethasone, Hydrocortisone)
|
Interactions mentioned but specific effects not detailed
|
| Disease Name | Risk Factors |
|---|---|
|
Hypersensitivity
|
Risk of allergic reactions
|
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.